VIEW WEBSITE >>
1 known investors
Enterprise Therapeutics develops novel drug therapies targeting the underlying mechanisms of mucus congestion in respiratory diseases including cystic fibrosis, asthma, and COPD. The company aims to reduce lung infection frequency and improve patient quality of life through disease-modifying treatments.
BiotechHealthtechMedical Devices